Comedown From Height of COVID Marks Shift for FDA Medtech Approval Strategy

The FDA is signaling a general slowdown of approvals for medtech innovations as the U.S. recovers from an interminable, not-officially-concluded COVID-19 pandemic as well as the global supply chain hold-ups that plagued nearly every major industry. The agency’s Device Center Director, Dr. Jeffrey Shuren...